OPEN END TURBO LONG - UNITED THERAPEUTICS Share Price

Certificat

DE000ME6CRT6

Market Closed - Börse Stuttgart 20:46:35 17/05/2024 BST
7.09 EUR +2.16% Intraday chart for OPEN END TURBO LONG - UNITED THERAPEUTICS
Current month+90.08%
1 month+81.33%
Date Price Change
17/05/24 7.09 +2.16%
16/05/24 6.94 -1.70%
15/05/24 7.06 +4.90%
14/05/24 6.73 +6.83%
13/05/24 6.3 -0.47%

Delayed Quote Börse Stuttgart

Last update May 17, 2024 at 08:46 pm

More quotes

Static data

Product typeKnock-Out without Stop Loss
Buy / SellCALL
Underlying UNITED THERAPEUTICS CORPORATION
Issuer Morgan Stanley
WKN ME6CRT
ISINDE000ME6CRT6
Date issued 03/01/2024
Strike 197.1 $
Maturity Unlimited
Parity 10 : 1
Emission price 2.84
Emission volume N/A
Settlement cash
Currency EUR

Technical Indicators

Highest since issue 7.19
Lowest since issue 1.83

Company Profile

United Therapeutics Corporation is a pharmaceutical company. It markets and sells commercial therapies to treat pulmonary arterial hypertension (PAH): Tyvaso DPI (treprostinil) Inhalation Powder (Tyvaso DPI); Tyvaso (treprostinil) Inhalation Solution (nebulized Tyvaso), which includes the Tyvaso Inhalation System; Remodulin (treprostinil) Injection (Remodulin); Orenitram (treprostinil) Extended-Release Tablets (Orenitram); and Adcirca (tadalafil) Tablets (Adcirca). Tyvaso DPI and nebulized Tyvaso are also approved to treat pulmonary hypertension associated with interstitial lung disease (PH-ILD). It also markets and sells an oncology product, Unituxin (dinutuximab) Injection (Unituxin) for treatment of high-risk neuroblastoma, and the Remunity Pump for Remodulin (Remunity). Tyvaso DPI is a drug-device combination product that incorporates the dry powder formulation technology and Dreamboat inhalation device technology used in MannKind’s Afrezza (insulin human) Inhalation Powder.
Sector
-
More about the company

Ratings for United Therapeutics Corporation

Trading Rating
Investor Rating
ESG Refinitiv
B+
More Ratings

Consensus: United Therapeutics Corporation

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
16
Last Close Price
274.3 USD
Average target price
292.7 USD
Spread / Average Target
+6.74%
Consensus